Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2012, 13(9), 11471-11496; doi:10.3390/ijms130911471
Review

Personalized Targeted Therapy for Lung Cancer

1
, 1
, 2
 and 3,*
Received: 7 August 2012; in revised form: 5 September 2012 / Accepted: 7 September 2012 / Published: 13 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
View Full-Text   |   Download PDF [569 KB, uploaded 19 June 2014]
Abstract: Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will most likely benefit from a treatment. In lung cancer, the well-developed epidermal growth factor receptor (EGFR) and the newly emerging EML4-anaplastic lymphoma kinase (ALK) are important therapeutic targets. This review covers the basic mechanism of EGFR and EML4-ALK activation, the predictive biomarkers, the mechanism of resistance, and the current targeted tyrosine kinase inhibitors. The efficacy of EGFR and ALK targeted therapies will be discussed in this review by summarizing the prospective clinical trials, which were performed in biomarker-based selected patients. In addition, the revolutionary sequencing and systems strategies will also be included in this review since these technologies will provide a comprehensive understanding in the molecular characterization of cancer, allow better stratification of patients for the most appropriate targeted therapies, eventually resulting in a more promising personalized treatment. The relatively low incidence of EGFR and ALK in non-Asian patients and the lack of response in mutant patients limit the application of the therapies targeting EGFR or ALK. Nevertheless, it is foreseeable that the sequencing and systems strategies may offer a solution for those patients.
Keywords: ALK; biomarker; EGFR; lung cancer; next-generation sequencing ALK; biomarker; EGFR; lung cancer; next-generation sequencing
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wu, K.; House, L.; Liu, W.; Cho, W.C. Personalized Targeted Therapy for Lung Cancer. Int. J. Mol. Sci. 2012, 13, 11471-11496.

AMA Style

Wu K, House L, Liu W, Cho WC. Personalized Targeted Therapy for Lung Cancer. International Journal of Molecular Sciences. 2012; 13(9):11471-11496.

Chicago/Turabian Style

Wu, Kehua; House, Larry; Liu, Wanqing; Cho, William C.S. 2012. "Personalized Targeted Therapy for Lung Cancer." Int. J. Mol. Sci. 13, no. 9: 11471-11496.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert